You are here

What’s the Stem Cells Buzz this Week? - Assessing Anti-tumor NSCs, Semaphorin 3A and Muscle Commitment, EPCR and Epidermal Stem Cells, and Adiponectin Control of Hematopoietic Regeneration!

Comment

Discuss

A roundup of some the recent stories in the ever-changing world of stem cells and regenerative medicine

Assessing the Migration and Distribution of Anti-tumor Engineered NSCs

In the hope of enhancing the development and refinement of neural stem cell (NSC)-based anti-tumor therapies, the lab of Michael E. Barish (Beckman Research Institute of the City of Hope, California, USA) has recently completed a study on NSC migration and tumor coverage. Their STEM CELLS study employed a quantitative analysis of immunostained serially sectioned formalin-fixed paraffin-embedded (FFPE) brain tissue to provide a framework to assess the mechanisms that promote and limit this NSC-based anti-tumor strategy.

Semaphorin 3A Commits to Slow Muscle Fiber Fate

Previous studies from the lab of Ryuichi Tatsumi (Kyushu University, Fukuoka, Japan) uncovered the expression of semaphorin 3A (Sema3A) in myogenic stem satellite cells in response to muscle injury. Their new STEM CELLS study now indicates that Sema3A commits stem cell differentiation to a slow muscle fiber fate during muscle regeneration. The authors hope that this finding will contribute to  the treatment of muscle-related diseases and even food security through meat‐animal production.

EPCR Marks the Spot for Epidermal Stem Cells

A new study from the lab of Meilang Xue (University of Sydney, South Wales, Australia) aspired to study the potential for Endothelial protein C receptor (EPCR) in the isolation of cells for the treatment of serious epithelial defects. Excitingly, Xue et al have now discovered that EPCR regulates p63, a stem cell marker, marks highly proliferative keratinocytes, and may aid in the isolation of human epidermal stem cells. See STEM CELLS now for all the cogent details on EPCR!

Hematopoietic Regeneration via Adiponectin and mTORC1

Finally this week, a study from Mineo Kurokawa (University of Tokyo, Japan) assessed how changes in the bone marrow (BM) following injury modulate hematopoietic stem cell (HSC) biology. The team’s new STEM CELLS study indicates that BM injury and the associated massive expansion of BM adipocytes leads to the release of adiponectin. This adipocyte-derived anti‐diabetic hormone then activates the HSC cell cycle to promote the replacement of lost hematopoietic cells. A great new study and intriguing new link!

So that’s a wrap for this week! Please let us know your views on all the stories we have covered here on the Stem Cells Buzz, and please let us know if we have missed anything interesting! Happy reading!